Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221 (market cap $29.60B), while Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $868.62M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 34.1× Amphastar Pharmaceuticals Inc's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | AMPH | |
|---|---|---|
Market Cap | $29.60B | $868.62M |
Sector | Health | Health |
52-Week High | $491.22 | $30.81 |
52-Week Low | $205.48 | $16.87 |
Enterprise Value | $27.56B | $1.27B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
